This study evaluates age related effects on CSF delivered lipid-siRNA conjugates, assessing biodistribution, safety, and efficacy. Comparisons between conjugate designs highlights structure dependent performance and provides insight into optimizing siRNA therapeutics for neurodegenerative disease treatment in aged CNS contexts.
